What they were paid
Entrada Therapeutics Director Compensation Table · the one fiscal year held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $63,038 | $0 | $104,388 | $1 | $167,427 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Entrada Therapeutics, Inc. DEF 14A filed April 24, 2026, accession 0001689375-26-000021, and prior-year filings. Open the filing on EDGAR.
Committees
FY2025 · as the proxy prints themAudit (Chair) · Compensation
The rest of the Entrada Therapeutics board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Bernhardt Zeiher, M.D | Independent Director | $150,680 |
| Dipal Doshi | Director | $0 |
| Gina Chapman | Independent Director | $157,553 |
| Kush M. Parmar, M.D., Ph.D | Chair of the Board | $202,597 |
| Maha Radhakrishnan, M.D | Independent Director | $230,927 |
| Peter S. Kim, Ph.D | Director | $144,388 |
The full Entrada Therapeutics compensation record
free company briefThis page is one director within Entrada Therapeutics's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat